Objective:
The objective of this study was to demonstrate diagnostic equivalence between the cardiac troponin I (cTnI) method on the point-of-care Stratus® CS/Stratus CS 200* Acute Care™ Diagnostic Systems and the laboratory-based ADVIA Centaur® TnI-Ultra® assay on the ADVIA Centaur XP Immunoassay System (all from Siemens Healthcare Diagnostics Inc.) in the determination of myocardial infarction (MI).
Relevance:
Troponin is recognized as the preferred biomarker in detection of MI given its high clinical sensitivity and myocardial tissue specificity. The Third Universal Definition of MI, endorsed by the European Society of Cardiology (ESC), the American College of Cardiology Foundation (ACCF), the American Heart Association (AHA), and the World Heart Federation (WHF) and adopted by the World Health Organization (WHO), requires at least one cTnI value above the 99th percentile upper reference limit (URL) during patient monitoring for detection of MI. The cTnI methods on the Stratus CS/Stratus CS 200* and ADVIA Centaur XP systems are considered guideline-acceptable as they each display optimal precision at their 99th percentile URL with a coefficient of variation (CV) ≤10%, allowing reliable detection of changing cTnI values.
Learn more about the systems evaluated
Stratus CS/Stratus CS 200* Acute Care Diagnostic Systems
Lab-quality results at the point of care with the speed that is needed for rapid decision making for better patient care.
ADVIA Centaur XP System
Enhanced productivity to meet peak workloads with optimal sample processing and a high level of efficiency.
Learn more about cardiac assays
Point-of-care Assays
Cardiac assays to meet your POC testing needs with first results in as fast as 14 minutes, and subsequent results in as fast as 4 minutes
ADVIA Centaur Systems Cardiac Assays
For earlier diagnosis of myocardial infarctions
